Downregulation of breast cancer resistance protein in colon adenomas reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen
Corresponding Author
Christoph G. Dietrich
Department of Gastroenterology and Hepatology, Aachen University, Aachen, Germany
Christoph G. Dietrich, Department of Medicine at Bethlehem-Hospital, Steinfeldstraße 5, 52222 Stolberg, Germany
Andreas Geier, Clinic for Gastroenterology and Hepatology, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
Search for more papers by this authorAnn-Kathrin Vehr
Department of Gastroenterology and Hepatology, Aachen University, Aachen, Germany
Search for more papers by this authorIna V. Martin
Department of Gastroenterology and Hepatology, Aachen University, Aachen, Germany
Search for more papers by this authorNikolaus Gaßler
Institute of Pathology, Aachen University, Aachen, Germany
Search for more papers by this authorTimo Rath
Department of Gastroenterology, Justus-Liebig-University Giessen, Giessen, Germany
Search for more papers by this authorElke Roeb
Department of Gastroenterology, Justus-Liebig-University Giessen, Giessen, Germany
Search for more papers by this authorJohannes Schmitt
Clinic of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorChristian Trautwein
Department of Gastroenterology and Hepatology, Aachen University, Aachen, Germany
Search for more papers by this authorCorresponding Author
Andreas Geier
Department of Gastroenterology and Hepatology, Aachen University, Aachen, Germany
Clinic of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland
Christoph G. Dietrich, Department of Medicine at Bethlehem-Hospital, Steinfeldstraße 5, 52222 Stolberg, Germany
Andreas Geier, Clinic for Gastroenterology and Hepatology, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
Search for more papers by this authorCorresponding Author
Christoph G. Dietrich
Department of Gastroenterology and Hepatology, Aachen University, Aachen, Germany
Christoph G. Dietrich, Department of Medicine at Bethlehem-Hospital, Steinfeldstraße 5, 52222 Stolberg, Germany
Andreas Geier, Clinic for Gastroenterology and Hepatology, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
Search for more papers by this authorAnn-Kathrin Vehr
Department of Gastroenterology and Hepatology, Aachen University, Aachen, Germany
Search for more papers by this authorIna V. Martin
Department of Gastroenterology and Hepatology, Aachen University, Aachen, Germany
Search for more papers by this authorNikolaus Gaßler
Institute of Pathology, Aachen University, Aachen, Germany
Search for more papers by this authorTimo Rath
Department of Gastroenterology, Justus-Liebig-University Giessen, Giessen, Germany
Search for more papers by this authorElke Roeb
Department of Gastroenterology, Justus-Liebig-University Giessen, Giessen, Germany
Search for more papers by this authorJohannes Schmitt
Clinic of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorChristian Trautwein
Department of Gastroenterology and Hepatology, Aachen University, Aachen, Germany
Search for more papers by this authorCorresponding Author
Andreas Geier
Department of Gastroenterology and Hepatology, Aachen University, Aachen, Germany
Clinic of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland
Christoph G. Dietrich, Department of Medicine at Bethlehem-Hospital, Steinfeldstraße 5, 52222 Stolberg, Germany
Andreas Geier, Clinic for Gastroenterology and Hepatology, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
Search for more papers by this authorAbstract
Several molecular changes in colorectal adenomas provide the basis of the adenoma–carcinoma sequence. We investigated the expression of xenobiotic ATP-binding cassette (ABC) transporters in humans and in ApcMin mice and conducted functional studies estimating the importance of the expression changes. Twenty-nine adenomas from 21 patients and eight adenomas from four ApcMin mice were analyzed using Western blotting and quantitative Real-time polymerase chain reaction (RT-PCR). Adjacent healthy tissue served as control for each polyp. Breast cancer resistance protein (BCRP) was significantly downregulated in human colorectal adenomas (to 28 ± 35% of adjacent healthy tissue). This was in line with data from ApcMin mice adenomas, where downregulation was significant as well (to 58 ± 34%). In parallel, quantitative RT-PCR showed BCRP mRNA downregulation in human adenomas (to 17 ± 31%). Basal multidrug resistance-associated protein 2 expression was low and did not change in adenomas; multidrug resistance transporter 1 expression also did not differ between adenomas and healthy tissue. In a functional study, ApcMin mice received radioactively labelled 2-amino-1-methyl-6-phenylimidazo[4,5-β] pyridine (PhIP), a food colon carcinogen and substrate of BCRP, by oral gavage with analysis of PhIP accumulation and DNA adduct formation 48 hr later. In this setting, we could demonstrate a higher carcinogen concentration in adenomas of ApcMin mice (181 ± 113% of normal tissue) including immunohistochemical detection of PhIP–DNA adducts. We conclude that significant transcriptional downregulation of BCRP/Bcrp leads to higher carcinogen concentrations in colorectal adenomas of mice and men. This might promote the adenoma–carcinoma sequence by higher genotoxic effects. The results indicate a possible role of transporter deficiencies in susceptibility for colon carcinoma.
References
- 1 Mandel JS. Screening for colorectal cancer. Gastroenterol Clin North Am 2008; 37: 97–115, vii.
- 2 Kwak EL, Chung DC. Hereditary colorectal cancer syndromes: an overview. Clin Colorectal Cancer 2007; 6: 340–4.
- 3 Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919–32.
- 4 Vogelstein B, Kinzler K. The genetic basis of human cancer. New York: McGraw-Hill, 1998.
- 5 Berlau J, Glei M, Pool-Zobel BL. Colon cancer risk factors from nutrition. Anal Bioanal Chem 2004; 378: 737–43.
- 6 Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis 1995; 16: 39–52.
- 7 Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003; 52: 1788–95.
- 8 Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361–98.
- 9 Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007; 1773: 283–308.
- 10 Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665–70.
- 11 Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61: 3458–64.
- 12 Dietrich CG, de Waart DR, Ottenhoff R, Bootsma AH, van Gennip AH, Elferink RP. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Carcinogenesis 2001; 22: 805–11.
- 13 Dietrich CG, de Waart DR, Ottenhoff R, Schoots IG, Elferink RP. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol Pharmacol 2001; 59: 974–80.
- 14 Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, Schinkel AH. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005; 11: 127–9.
- 15 van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, Schinkel AH. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine. Cancer Res 2003; 63: 6447–52.
- 16 Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002; 99: 15649–54.
- 17 Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, Bates SE. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59: 5938–46.
- 18 Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH, Schinkel AH. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann N Y Acad Sci 2000; 922: 188–94.
- 19 Gupta N, Martin PM, Miyauchi S, Ananth S, Herdman AV, Martindale RG, Podolsky R, Ganapathy V. Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem Biophys Res Commun 2006; 343: 571–7.
- 20 Dietrich CG, Geier A, Salein N, Lammert F, Roeb E, Oude Elferink RP, Matern S, Gartung C. Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2. Gastroenterology 2004; 126: 1044–53.
- 21 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 1976; 72: 248–54.
- 22 Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157: 1575–80.
- 23 Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 2004; 279: 25527–34.
- 24 Shirai T, Takahashi S, Cui L, Yamada Y, Tada M, Kadlubar FF, Ito N. Use of polyclonal antibodies against carcinogen-DNA adducts in analysis of carcinogenesis. Toxicol Lett 1998; 102–103: 441–6.
- 25 Zhu J, Rashid A, Cleary K, Abbruzzese JL, Friess H, Takahashi S, Shirai T, Li D. Detection of 2-amino-1-methyl-6-phenylimidazo [4,5-b]-pyridine (PhIP)-DNA adducts in human pancreatic tissues. Biomarkers 2006; 11: 319–28.
- 26 WCRF/AICR. Food, nutrition and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer research, 1997.
- 27 Gaylor DW KF. Quantitative cancer risk assessment of heterocyclic amines in cooked foods. In: H. Hayatsu Mutagens in food: detection and preventioned. Boca Raton, FL: CRC Press, 1991. 229–36.
- 28 Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 2005; 433: 387–96.
- 29 Anapolsky A, Teng S, Dixit S, Piquette-Miller M. The role of pregnane X receptor in 2-acetylaminofluorene-mediated induction of drug transport and -metabolizing enzymes in mice. Drug Metab Dispos 2006; 34: 405–9.
- 30 Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004; 279: 24218–25.
- 31 Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, Katano M. Inhibition of Wnt signaling pathway decreases chemotherapy- resistant side-population colon cancer cells. Anticancer Res 2010; 30: 2041–8.
- 32 D'Errico I, Moschetta A. Nuclear receptors, intestinal architecture and colon cancer: an intriguing link. Cell Mol Life Sci 2008; 65: 1523–43.
- 33 Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317: 124–7.